Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression

Experimental Neurology

Volumn 144, Issue 2, 1997, Pages 423-432

  Duty, Susan ^a   Brotchie, Jonathan M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; OXIDOPAMINE; PREPROENKEPHALIN; PRODYNORPHIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RAT;

EID: 0031128414     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6431     Document Type: Article

References (44)

1. Angulo J. A., McEwen B. S. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. Brain. Res. Rev. 19:1994;1-28.
2. Bevan P. Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity. Neurosci. Letts. 35:1983;185-189.
3. Breslin M. B., Lindberg I., Benjannet S., Mathis J. P., Lazure C., Seidah N. Differential processing of proenkephalin by prohormone convertases 1(3) and 2 and furin. J. Biol. Chem. 269:1993;27084-27093.
4. 314. Exp. Neurol. 113:1991;171-181.
5. Brotchie J., Henry B., Duty S. The role of opioid peptides in the neural mechanisms underlying L-DOPA-induced dyskinesias in Parkinson's disease. Soc. Neurosci. 21:1995;560-563.
6. Buonamici M., Caccia C., Carpentieri M., Pegrassi L., Rossi A. C., DiChiara G. D-1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. Eur. J. Pharmacol. 126:1986;347-348.
7. Carey R. J. Chronic L-DOPA treatment in the unilateral 6-OHDA rat: evidence for behavioural sensitization and biochemical tolerance. Brain Res. 568:1991;205-214.
8. Chavkin C., James I. F., Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. 215:1982;413-415.
9. Civelli O., Douglass J., Goldstein A., Herbert E. Sequence and expression of the rat prodynorphin gene. Proc. Natl. Acad. Sci. USA. 82:1985;4291-4295.
10. Corbett A. D., Paterson S. J., McKnight A. T., Magnan J., Kosterlitz H. W. Dynorphin1-8 and dynorphin1-9 are ligands for the kappa-subtype of opiate receptor. Nature. 299:1982;79-81.
11. Del Fiacco M., Paxinos G., Levanti M. C. Neostriatal enkephalin immunoreactive neurons project to the globus pallidus. Brain Res. 231:1982;1-17.
12. Deshaies P., Bédard P., Falardeau P., Di Paolo T. Behavioural and biochemical evidence of apomorphine-induced supersensitivity of the striatal dopamine receptors. Neuropharmacology. 23:1984;1219-1222.
13. Dupuy A., Lindberg I., Zhou Y., Akil H., Lazure C., Chretien M., Seidah N. G., Day R. Processing of prodynorphin by the prohormone convertase PC1 results in high molecular weight intermediate forms. Cleavage at single arginine residues. FEBS Lett. 337:1994;60-65.
14. Duty S., Henry B., Crossman A. R., Brotchie J. M. Speculations on the neural mechanisms underlying the dyskinetic side-effects of dopamine replacement therapy in parkinsonism. Brain Res. Assoc. 12:1995;41.2.
15. Duty S., Henry B., Crossman A. R., Brotchie J. M. Speculations on the molecular mechanisms underlying dopamine agonist-induced dyskinesias in parkinsonism. The Basal Ganglia V. 1996;Plenum Press. p. 347-355.
16. Engber T. M., Susel Z., Kuo S., Gerfen C. R., Chase T. N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552:1991;113-118.
17. Fort P., Marty L., Piechaczyk M., El Sabrouty S., Dani C., Jeanteur P., Blanchard J. M. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res. 13:1985;1431-1441.
18. Gerfen C. G., Young III W. S. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: An in situ hybridisation histochemistry and fluorescent retrograde tracing study. Brain Res. 460:1988;161-167.
19. Gerfen C. R., McGinty J. F., Young III W. S. Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: In situ hybridisation histochemical analysis. J. Neurosci. 11:1991;1016-1031.
20. 21. Brain Res. 514:1990;93-102.
21. Groppetti A., Flauto C., Parati E., Vescovi A., Rusconi L., Parenti M. Dopamine receptor changes in response to prolonged treatment with L-DOPA. J. Neural. Transm. Suppl. 22:1986;33-45.
22. Hammond C., Feger J., Biolac B., Souteyrend J. P. Experimental hemiballismus produced by unilateral kainic acid lesion in the corpus Luysii. Brain Res. 171:1979;577-580.
23. Henry B., Brotchie J. M. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging. 9:1996;1-10.
24. Howells R. D., Kilpatrick D. L., Bhatt R., Monahan J. J., Poonian M., Udenfriend S. Molecular cloning and sequence determination of rat preproenkephalin cDNA: Sensitive probes for studying transcriptional changes in rat tissues. Proc. Natl. Acad. Sci. USA. 81:1984;7651-7655.
25. Kieffer B. L. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cellular and Molecular Neurobiology. 15:1995;615-635.
26. 2. Neuroscience. 53:1993;665-672.
27. Li S. J., Jiang H. K., Stachowiak M. S., Hudson P. M., Owyang V., Nanry K., Tilson H. A., Hong J. S. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. Mol. Brain Res. 8:1990;219-225.
28. Maneuf Y. P., Mitchell I. J., Crossman A. R., Brotchie J. M. On the role of enkephalin in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol. 125:1994;65-71.
29. Maneuf Y. P., Mitchell I. J., Crossman A. R., Woodruff G. N., Brotchie J. M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res. 683:1995;102-108.
30. Marsden C. D., Parkes J. D. Success and problems of long term therapy in Parkinson's disease. Lancet. 1:1977;345-349.
31. Martin J. P. Hemichorea resulting from a local lesion of the brain (syndrome of body of Luys). Brain. 50:1927;637-651.
32. Mitchell I. J., Jackson A., Sambrook M. A., Crossman A. R. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Res. 339:1985;346-350.
33. Mitchell I. J., Jackson A., Sambrook M. A., Crossman A. R. The role of the subthalamic nucleus in experimental chorea: Evidence from 2-deoxyglucose autoradiography. Brain. 112:1989;1533-1548.
34. Mitchell I. J., Luquin R., Boyce S., Clarke C. E., Robertson R. G., Sambrook M. A., Crossman A. R. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Movement Disorders. 5:1990;49-54.
35. Mitchell I. J., Boyce S., Sambrook M. A., Crossman A. R. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain: implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain. 115:1992;809-824.
36. Normand E., Popovici T., Onteniente B., Fellmann D., Piatier-Tonneau D., Auffray C., Bloch B. Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons. Brain Res. 439:1988;39-46.
37. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press.
38. Rosen H., Douglass J., Herbert E. Isolation and characterisation of the rat proenkephalin gene. J. Biol. Chem. 259:1984;14309-14313.
39. Trabucchi M., Bassi S., Frattola L. Effect of naloxone on the 'On-Off' syndrome in patients receiving long-term levodopa therapy. Arch. Neurol. 39:1982;120-121.
40. Ungerstedt U., Avema A. E., Ljundberg T., Runge C. Animal models of parkinsonism. Adv. Neurol. 3:1973;257-271.
41. Vincent S. R., Hökfelt T., Christensson I., Terenius L. Immunohistochemical evidence for a dynorphin immunoreactive strionigral pathway. Eur. J. Pharmacol. 85:1982;251-252.
42. Whittier J. R., Mettler F. A. Studies on the subthalamus of rhesus monkey. II. Hyperkinesia and other physiological effects of subthalamic lesions, with special reference to the subthalamic nucleus of Luys. J. Comp. Neurol. 90:1949;319-372.
43. Young III W. S., Bonner T. I., Brann M. R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
44. Zamir N., Palkovits M., Weber E., Mezey E., Brownstein M. J. A dynorphinergic pathway of Leu-enkephalin production in rat substantia nigra. Nature. 307:1984;643-645.